Menu Menu Menu
Nice Insight Research
Content Menu
Menu Menu Menu
To Top

Search By Topic

Clinical Trial

245 Articles available
Clinical Trial

Xeris Pharmaceuticals and OHSU Conducting Artificial Pancreas Clinical Trial Using Xeris’ Novel Ready-to-Use Liquid Glucagon

PR-M09-18-NI-066
Clinical Trial

Trovagene Announces Completion of Second Dosing Cohort of Patients Treated with Onvansertib (PCM-075) in Ongoing Phase 1b/2 AML Trial

PR-M09-18-NI-061
Clinical Results

Biohaven Reports Positive Results From Double-Blind, Placebo-Controlled, Investigator Initiated, Proof Of Concept Trial Of BHV-0223 For Anxiety

PR-M09-18-NI-060
Drug Development

Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2018 World Congress on Parkinson's Disease and Related Disorders

PR-M09-18-NI-058
Study Results

Regeneron and Teva Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip

PR-M09-18-NI-059
Phase II

Peptide Logic Awarded A $ 2.9 Million SBIR Phase II Grant To Develop Peripherally-Restricted And Long-Acting Kappa-Opioid Receptor (LA-KOR) Agonists For Moderate-To-Severe Pain

PR-M09-18-NI-056
Study Results

Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip

PR-M09-18-NI-051
Clinical Data

Actinium to Provide Update on Pivotal Phase 3 SIERRA Trial Following Positive Data Monitoring Committee Meeting

PR-M09-18-NI-043
Study Results

Janssen Reports Positive Topline Results for ATLAS Phase III Study of a Novel, Long Acting Injectable Two-Drug Regimen for the Treatment of HIV-1

PR-M09-18-NI-045
Phase 2

Oragenics, Inc. Resumes Phase 2 Clinical Trial of AG013 in Oral Mucositis Following Positive Routine Safety Review

PR-M09-18-NI-041
Research

Novocure and US Oncology Research Announce Collaboration on PANOVA-3 Trial for Patients with Advanced Pancreatic Cancer

PR-M09-18-NI-040
Oncology

CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study

PR-M09-18-NI-038
Clinical Study

Electromed, Inc. Announces Results of an Independent Clinical Study: Bronchiectasis Exacerbations Reduced, Lung Function Stabilized with SmartVest®

PR-M09-18-NI-037
Preclinical Data

Synlogic Publishes Preclinical Data Supporting Development of SYNB1618, a Synthetic Biotic™ Medicine as a Potential Treatment for Phenylketonuria

PR-M09-18-NI-026
Clinical Trials

Entasis Therapeutics Announces Positive Topline Results from Phase 2 Trial of ETX2514SUL in Patients with Complicated Urinary Tract Infections including Acute Pyelonephritis

PR-M09-18-NI-024
Biosimilar

JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Bevacizumab Biosimilar to Treat Lung Cancer

PR-M09-18-NI-013
Clinical Trial

First Patient Dosed in Phase 1/2 Study Evaluating SOBI003 for Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)

PR-M09-18-NI-012
Clinical Use

Conavi Medical Announces Clinical Use of the Novasight Hybrid System with Simultaneous Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT) Capabilities

PR-M09-18-NI-009
Phase I

Samsung Bioepis to Initiate Phase 1 Clinical Trial of SB26 Ulinastatin-Fc Fusion Protein

PR-M09-18-NI-007
Clinical Trials

GI Dynamics Announces FDA Approval for EndoBarrier Pivotal Trial

PR-M09-18-NI-006
Clinical Trial

Enrollment Passes Halfway Milestone in Clinical Trial Evaluating the Effect of an Exclusive Human Milk Diet

PR-M08-18-NI-122
Study Results

VolitionRx Limited Announces Completion of Sample Collection in Endometriosis Study

PR-M08-18-NI-119
Clinical Trial

I-Mab's Announces China Clinical Trial Approval of Long-acting hGLP-1 to Treat Type 2 Diabetes

PR-M08-18-NI-116
FDA Guidance

FDA Published Draft Guidance on Use of Placebo Control Groups

PAO-M08-18-NI-029
Clinical Data

Novartis Reports Promising Results for its New Alpha Specific PI3K Inhibitor BYL719

PAO-M08-18-NI-028
Clinical Trial

Sangamo Announces Positive Preliminary Data from the Phase 1/2 Alta Study Evaluating SB-525 Gene Therapy for Hemophilia A

PR-M08-18-NI-113
Clinical Trial

Clovis Oncology Announces First Patient Enrolled in the Phase 3 ATHENA Trial

PR-M08-18-NI-085
Clinical Trial

Milestone Pharmaceuticals Announces First Patient Randomized in the Phase 3 NODE-301 Clinical Trial Evaluating Etripamil for Termination of Paroxysmal Supraventricular Tachycardia (PSVT) Episodes

PR-M08-18-NI-098
Clinical Trial

First Participant Enrolled in BiondVax's Universal Flu Vaccine Pivotal Phase 3 Clinical Trial

PR-M08-18-NI-095
Supply Chain

Marken Offers First Hybrid Service from Brazil to USA

PR-M08-18-NI-124
Clinical Trials

60 Day Window for Clinical Trial Approval Official, says George Clinical, a leading Asia-Pacific CRO

PR-M08-18-NI-123
Clinical Trials

Xcovery Announces First Cohort of Patients Dosed in a Phase 1/2 Clinical Trial of Vorolanib

PR-M08-18-NI-035
Opening

DPS Group and TRIA Celebrate Opening of State-of-the-Art cGMP mRNA Clinical Manufacturing Facility for Moderna Therapeutics

PR-M07-18-NI-077
Clinical Trials

Allergan and Molecular Partners Announce Two Positive Phase 3 Clinical Trials

PR-M07-18-NI-067
Announcement

Cook® Regentec Announces First U.S. Clinical Use of Advance® CS Coronary Sinus Infusion Catheter to Deliver a Therapeutic in Heart Failure Patients

PR-M07-18-NI-063
Phase 3

PainReform Gets FDA Approval for Phase III Post-Operative Pain Relief Study

PR-M07-18-NI-062
Clinical Data

Eisai Inc. Announces Positive Topline Results from CAMELLIA-TIMI 61, a Large-Scale Cardiovascular Outcome Trial for the Anti-Obesity Agent BELVIQ®

PR-M07-18-NI-056
FDA Approval

U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

PR-M07-18-NI-047
Diabetes

Diabetes Research Institute Launches New Clinical Trial to Explore Effects of Omega-3 Fatty Acids and Vitamin D in Type 1 Diabetes

PR-M07-18-NI-043
Clinical Trials

CStone's PD-1 inhibitor CS1003 receives clinical trial approval in China

PR-M07-18-NI-042
Clinical Research

Eating Well Might Improve Cancer Treatments

PAO-M07-18-NI-006
Drug Development

SCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal Candidiasis

PR-M07-18-NI-039
Clinical Study

BioArctic Receives Regulatory Approval in Finland for a Clinical Study in Patients With Complete Spinal Cord Injury

PR-M07-18-NI-033
Oncology

Phase III IMpassion130 study showed Roche’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening for metastatic triple negative breast cancer

PR-M07-18-NI-021
Clinical Data

Mallinckrodt Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar® Gel (Repository Corticotropin Injection) Achieves its Enrollment Target

PR-M07-18-NI-009
Biosimilars

Amgen Announces Top-Line Results From Phase 3 Study Of ABP 710, Biosimilar Candidate To Infliximab

PR-M06-18-NI-100
Clinical Trials

Javara Launches Next Generation Integrated Clinical Trials Platform

PR-M06-18-NI-088
Clinical Trials

Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases

PR-M06-18-NI-091
Clinical Trials

Arcus Biosciences and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Lead Programs in Triple-Combination Studies

Clinical Data

Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In

PR-M06-18-NI-086
Clinical Trials

Oramed Enrolls First Patient in Its Glucose Clamp Study for Oral Insulin

PR-M06-18-NI-083
Clinical Trials

Aminex Therapeutics Initiates First Clinical Trial of Novel Immunotherapy AMXT 1501 + DFMO in Cancer Patients

PR-M06-18-NI-072
Clinical Trials

Array BioPharma to Present Overall Survival Results from the Phase 3 LUNGevity Takes Step Forward in Clinical Trial Eligibility Reform for Lung Cancer Patients

PR-M06-18-NI-062
Clinical Data

Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL

PR-M06-18-NI-062
Clinical Trials

BioMarin Doses First Participant in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia

PR-M06-18-NI-059
Clinical Trials

Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meeting

PR-M06-18-NI-060
Trial Results

Merck KGaA, Darmstadt, Germany Provides Update on Tepotinib Phase II Results in Advanced Hepatocellular Carcinoma

PR-M06-18-NI-041
Clinical Data

More Positive Phase 3 Results for Roche’s Tecentriq

PAO-M05-18-NI-024
Clinical Trials

Supporting Patient-Centric Clinical Trials from Point-of-Origin through the Last Mile

PAP-Q2-18-CL-002
Clinical Trials

Splash Pharmaceuticals Announces Dose Escalation in Phase I Clinical Trial in Platinum-resistant Ovarian Cancer Patients

PR-M05-18-NI-109
Clinical Trial

Sanofi: Accelerating Future Breakthroughs Through Clinical Trials -- Part 2 of 3

PR-M05-18-NI-080
Clinical Trial

Research Ready™ Program Expands and Diversifies Clinical Trial Patient Populations

PR-M05-18-NI-065
Oncology

Roche’s TECENTRIQ (Atezolizumab) Receives Priority Review

PAO-M05-18-NI-009
Clinical Trials

Merck Provides Update on KEYNOTE-407 Trial

PR-M05-18-NI-026
Clinical Data

Study Shows AST-005 is Safe and Tolerable in Patients at Higher Doses than Previously Studied

PAO-M05-18-NI-003
Clinical Data

DiscGenics Announces First Patient Treated in U.S. Clinical Trial of IDCT for Degenerative Disc Disease

PR-M04-18-NI-004
Clinical Trials

Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home

PR-M04-18-NI-100
Clinical Trials

AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients

PR-M04-18-NI-102
Vaccine

Vaccibody moving forward with Cancer Neoantigen Vaccine Trial

PR-M04-18-NI-79
Clinical Trials

Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery

PR-M04-18-NI-51
FDA

Kadmon Receives FDA Guidance on Pivotal Clinical Trial Design for KD025 in Chronic Graft-Versus-Host Disease

PR-M04-18-NI-46
Oncology

New Breast Cancer Drug Accepted for Review by EMA

PAO-M04-18-NI-010
Clinical Trials

Eli Lilly Gets Good News for Cyramza

PAO-M04-18-NI-009
Clinical Trials

First Patient Treated in Pivotal Phase 3 Trial to Evaluate OTL38 in the Detection of Ovarian Cancer

PR-M04-18-NI-33
Clinical Trials

SELLAS Life Sciences Announces Positive Interim Data from Phase 2b NeuVax™ (nelipepimut-S) Clinical Trial

PR-M04-18-NI-020
Results

Allergan and Richter Announce Positive Topline Results from Third of Three Pivotal Trials of Cariprazine in Bipolar I Depression

PR-M04-18-NI-018
Results

Positive Results for Pfizer Drug Tafamidis

PAO-M04-18-NI-001
Clinical Trials

MediciNova Announces Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD will be Terminated Early based on Significant Positive Results from Interim Analysis

PR-M04-18-NI-014
Clinical Trials

Pfizer Announces Positive Topline Results From Phase 3 ATTR-ACT Study Of Tafamidis In Patients With Transthyretin Cardiomyopathy

PR-M04-18-NI-006
Clinical Trials

Wize Pharma Enrolls First Patient in Phase IV Study of LO2A for Symptomatic Treatment of Dry Eye Syndrome in Patients With Sjögren's Syndrome

PR-M04-18-NI-005
Clinical Trials

Final results from landmark DYNAGITO® trial published in The Lancet Respiratory Medicine

PR-M04-18-NI-001
Clinical Data

Clinical Study Data for New MS Drug Looks Promising

PR-M03-18-NI-101
Clinical Trials

BrainStorm Cell Therapeutics' Phase 3 Trial of NurOwn® in ALS Now Open to Canadian Patients

PR-M03-18-NI-108
Clinical Data

New Study finds younger aged children with symptoms of ADHD have reduced brain size

PR-M03-18-NI-101
Clinical Trials

Clinical Trial Access to Expand Following Receipt of Additional Funding    

PAO-M03-18-NI-026
Clinical Trials

Ipsen Receives Positive CHMP Opinion for Cabometyx®  (cabozantinib) for the First-Line Treatment of Adults with Intermediate- or Poor- Risk Advanced Renal Cell Carcinoma

PR-M03-18-NI-096
Clinical Data

Phase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS

PR-M03-18-NI-095
Clinical Trials

Pfizer Reports Top-Line Results from a Study of CHANTIX®/CHAMPIX®  (varenicline) in Adolescent Smokers

PR-M03-18-NI-093
Clinical Trials

AbbVie Announces Results from Phase 2 Study Evaluating Rovalpituzumab Tesirine (Rova-T)

PR-M03-18-NI-088
Clinical Trial Data

Favorable safety profile of Pradaxa® (dabigatran etexilate) confirmed in large prospective real-world analysis

PR-M03-18-NI-086
Clinical Trials

Late-breaking Clinical Trial Data Further Demonstrate Safety and Effectiveness of the RHYTHMIA™ Mapping System

PR-M03-18-NI-083
Acquisition

Worldwide Clinical Trials Acquires Continuum Clinical’s Late Stage Research Practice

PR-M03-18-NI-065
Research

PAREXEL and CHA Medical Group Partner to Enhance Early Phase Clinical Research in Korea

PR-M03-18-NI-056
Clinical Trials

AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids

PR-M03-18-NI-057
Innovation

Bruker and Evosep Announce New Integrated Clinical Research Proteomics Solution to Quantify Over a Thousand Proteins in Five Minutes

PR-M03-18-NI-051
Acquistion

Biogen to Acquire from Pfizer First-in-Class Phase 2b Ready Asset for Cognitive Impairment Associated with Schizophrenia

PR-M03-18-NI-049
Laboratory Testing

Creating Comprehensive Solutions through Laboratory Testing

PAP-Q1-18-CL-011
Supply Chain

Overcoming Challenges in the Complex Market for Clinical Trials and Clinical Logistics

PAP-Q1-18-CL-010
Clinical Trials

Merck KGaA, Darmstadt, Germany, Announces Positive Phase IIB Results for Evobrutinib in Relapsing Multiple Sclerosis

PR-M03-18-NI-038
Results

Lilly Reports Results of Migraine Survey

PAO-M03-18-NI-007
Innovation

Results of Landmark Wearable Defibrillator Trial to Be Presented as ACC.18 Late-Breaker

PR-M03-18-NI-026
Clinical Trials

Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope

PR-M03-18-NI-021
Clinical Trials

The UPS Store, Marken Team Up For Drop-Off Service For Clinical Trial Samples In U.S.

PR-M03-18-NI-007
Drug Development

HEPAXA is a New Treatment in the US from BASF for Patients with NAFLD

PAO-M02-18-NI-023
Influenza

GSK presents new efficacy data for FLUARIX® QUADRIVALENT (Influenza Vaccine) in children 6 months through 35 months of age

PR-M02-18-NI-87
Clinical Trials

Aimmune’s AR101 Meets Phase 3 Endpoints

PAO-M02-18-NI-020
Clinical Trials

AbbVie Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endoscopic Outcomes in Crohn's Disease at 52 Weeks

PR-M02-18-NI-83
Oncology

Device Plus Drug Approved for Bladder Cancer Detection

PAO-M02-18-NI-018
Clinical Trials

Breakthrough Scar Treatment in Clinical Trials

PAO-M02-18-NI-016
Clinical Trials

Mallinckrodt Enrolls First Patient in Phase 1 Study of ExpressGraft™C9T1 Skin Tissue

PR-M02-18-NI-74
Drug Development

Merck Announces Discontinuation of APECS Study Evaluating Verubecestat (MK-8931) for the Treatment of People with Prodromal Alzheimer’s Disease

PR-M02-18-NI-70
Phase 3

Lilly Announces Positive Top-Line Phase 3 Results for Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

PR-M02-18-NI-61
Clinical Trials

Encorafenib and Binimetinib Combination Treatment Demonstrates 33.6 Month Median Overall Survival (OS) in Patients with BRAF-Mutant Melanoma

PR-M02-18-NI-043
Clinical Trials

Tyzivumab is Ready for Trials

PAO-M02-18-NI-011
Market Expansion

Marken Accelerates Its Reach And Growth In Clinical Trial Logistics

PR-M02-18-NI-031
Clinical Trials

Novartis Announces NEJM Publication Of Updated Analysis From ELIANA Trial Showing Longer-Term Durable Remissions With Kymriah™ In Children, Young Adults With r/r ALL

PR-M02-18-NI-019
Clinical Trials

COPD Patients Excited about AstraZeneca Trial Results

PAO-M02-18-NI-002
Fast Track

FDA Grants Fast Track Status to Takeda’s Zika Vaccine Candidate

PAO-M02-18-NI-003
Clinical Trials

Rexgenero Treats First Patient in its Phase III Programme with Lead Product REX-001, a Novel Cell Therapy for the Treatment of Critical Limb Ischemia (CLI)

PR-M01-18-NI-093
Clinical Trial

Amgen and Novartis Reach an Important Milestone

PAO-M01-18-NI-041
Oncology

Overall Survival Analysis From KYPROLIS® (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical Oncology

PR-M01-18-NI-074
Clinical Trials

Celerion Creates a Fully Automated, Early Development Clinical Trial Data Management Platform

PR-M01-18-NI-070
Expanded Capacity

Marken Opens New Kit Building Facility In Shanghai

PR-M01-18-NI-057
Treatment

First Treatment for MERS Appears Safe in NIH Phase I Clinical Trial

PR-M01-18-NI-041
Research

Medical Research Collaborating Center Selects Medidata to Meet Global Regulatory Requirements During Clinical Trials

PR-M01-18-NI-037
Clinical Trials

BerGenBio Meets First Efficacy Endpoint in Phase II Trial With Selective AXL Inhibitor BGB324 (bemcentinib) in NSCLC

PR-M01-18-NI-035
Bioequivalence Study

Biohaven Announces Positive Results From Bioequivalence Study With Sublingual BHV-0223 Zydis® Orally Dissolving Tablet

PR-M01-18-NI-034
Biologics

New Class of Exosome Biologics Focuses on Stroke Treatment

PAO-M01-18-NI-011
Drug Discovery

Defense Department Commits $16 Million to Fight Bacterial Bioweapons

PAO-M01-18-NI-010
Clinical Data

DNAnexus Announces $58 Million Investment to Accelerate Expansion

PR-M01-18-NI-004
Clinical Trials

Centrexion Therapeutics Raises $67 Million; Launching Phase 3 Program for CNTX-4975 in Knee Osteoarthritis Pain in 2018

PR-M01-18-NI-002
Strategic Partnership

Mitochondrial Expert Mitobridge Snapped Up by Astellas Pharma

PAO-M01-18-NI-002
Biosimilars

Pfizer Receives FDA Approval for Remicade® Biosimilar

PAO-M12-17-NI-039
Drug Delivery

Needle-Free Injection Technology Advances to Phase II Trial

PAO-M12-17-NI-035
Investment

Transporters Targeting Cell’s Metabolic Gates Win Financing

PAO-M12-17-NI-037
Drug Delivery

Needle-Free Injection Technology Advances to Phase II Trial

PAO-M12-17-NI-035
FDA

NDA Submitted for Antimalarial Drug

PAO-M12-17-NI-034
Research

Tumor Killing Combo Wins Third U.S. Patent

PAO-M12-17-NI-033
Drug Development

Chinese Biopharma Receives Series A Financing

PAO-M12-17-NI-031
Strategic Partnership

BioVectra and Keryx Expand Strategic API Supply Relationship

PAO-M12-17-NI-030
×